GW Pharma (GWPH) Outpaces Q1 Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results and Operational Progress
February 10, 2016 7:00 AM EST-Three Phase 3 Epidiolex clinical trials fully recruited above target sample size on track for initial data in March 2016-
-Conference Call Today at 8:00 a.m. EST, 1:00 p.m. GMT-
LONDON, Feb. 10, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH) (AIM: GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the first quarter ended 31... More
